Table 3.
Demographic and therapeutic exposure among cases and controls
| Including non-melanoma skin cancer |
Excluding non-melanoma skin cancer |
|||||
|---|---|---|---|---|---|---|
| Characteristics | Cases N (%) |
Controls N (%) |
P value | Cases N (%) |
Controls N (%) |
P value |
| Number of patients | 60 | 60 | 42 | 42 | ||
| Gender | ||||||
| Female | 17 (28%) | 26 (43%) | 12 (29%) | 18 (43%) | ||
| Male | 43 (72%) | 34 (57%) | 0.09 | 30 (71%) | 24 (57%) | 0.19 |
| Race/ethnicity | ||||||
| Others | 11 (18%) | 22 (37%) | 11 (26%) | 16 (38%) | ||
| Non-Hispanic Caucasian | 49 (82%) | 38 (63%) | 0.02 | 31 (74%) | 26 (62%) | 0.15 |
| Age at MM diagnosis | ||||||
| <55 | 24 (40%) | 38 (63%) | 21 (50%) | 27 (64%) | ||
| ≥55 | 36 (60%) | 22 (37%) | 0.01 | 21 (50%) | 15 (36%) | 0.14 |
| Pre-ASCT exposure | ||||||
| Pre-HCT radiation | 20 (33%) | 17 (28%) | 0.51 | 14 (33%) | 12 (29%) | 0.59 |
| Cyclophosphamide | 7 (12%) | 12 (20%) | 0.23 | 6 (14%) | 9 (21%) | 0.41 |
| Doxorubicin | 42 (70%) | 47 (78%) | 0.18 | 32 (76%) | 34 (81%) | 0.53 |
| Etoposide | 7 (12%) | 5 (8%) | 0.48 | 6 (14%) | 3 (7%) | 0.27 |
| Prednisone | 19 (32%) | 15 (25%) | 0.40 | 15 (36%) | 14 (33%) | 0.81 |
| Thalidomide | 22 (37%) | 19 (32%) | 0.29 | 14 (33%) | 11 (26%) | 0.27 |
| Vincristine | 40 (67%) | 48 (80%) | 0.04 | 30 (71%) | 35 (83%) | 0.12 |
| Priming agents* | ||||||
| Cyclophosphamide | 40 (70%) | 38 (69%) | 1.00 | 23 (59%) | 25 (66%) | 0.18 |
| Paclitaxel | 9 (16%) | 12 (22%) | 0.37 | 6 (15%) | 10 (26%) | 0.14 |
| Conditioning agents** | ||||||
| Total Body Irradiation | 9 (16%) | 10 (18%) | 0.74 | 7 (18%) | 9 (24%) | 0.42 |
| Busulfan | 16 (29%) | 18 (33%) | 0.53 | 10 (26%) | 11 (29%) | 0.71 |
| Cyclophosphamide | 19 (35%) | 22 (40%) | 0.37 | 13 (34%) | 15 (39%) | 0.48 |
| Etoposide | 3 (5%) | 4 (7%) | 0.57 | 3 (8%) | 4 (11%) | 0.57 |
| Melphalan | 50 (90%) | 49 (89%) | 0.57 | 34 (89%) | 33 (87%) | 0.57 |
| Post-ASCT exposure | ||||||
| Dexamethazone | 19 (35%) | 14 (25%) | 0.28 | 12 (35%) | 10 (25%) | 0.59 |
| Interferon α | 18 (33%) | 16 (29%) | 0.59 | 12 (33%) | 12 (29%) | 1.00 |
| Prednisone | 5 (10%) | 3 (5%) | 0.42 | 5 (10%) | 3 (5%) | 0.42 |
| Thalidomide | 30 (50%) | 26 (47%) | 0.29 | 19 (50%) | 18 (47%) | 0.74 |
| Thalidomide exposure timing | ||||||
| None | 21 (35%) | 26 (44%) | 16 (38%) | 19 (45%) | ||
| Pre-ASCT | 9 (15%) | 8 (13%) | 0.19 | 7 (17%) | 5 (12%) | 0.17 |
| Post-ASCT | 17 (28%) | 15 (25%) | 0.15 | 12 (28%) | 12 (29%) | 0.42 |
| Both pre- and post-ASCT | 13 (22%) | 11 (18%) | 0.12 | 7 (17%) | 6 (14%) | 0.26 |
| Either pre- or post-ASCT | 39 (65%) | 34 (56%) | 0.12 | 26 (62%) | 23 (55%) | 0.27 |
*
3 cases and 5 controls without information about priming agents.
**
5 cases and 5 controls without conditioning information.
ASCT=autologous stem cell transplantation, MM=multiple myeloma